Abstract 11598: Increased Advanced Glycation End-Products Accelerate the Progress of Left Ventricular Hypertrophy Under Condition of Elevated Oxidative Stress or Insulin Resistance in Patients With Hypertension
Authors: Aoyama Akihiro, Masuda Takashi, Ogura Misao, Shimizu Ryosuke, Kato Michitaka, Kamekawa Daisuke, Kamada Yumi, Tanaka Shinya, Kamiya Kentaro, Hamazaki Nobuaki, Maekawa Emi, Tojo Y Minako, Ako Junya
Journal: Circulation (2014)

Background: Elevated oxidative stress or insulin resistance has been shown to promote the production of advanced glycation end-products (AGEs) in patients with hypertension (HT). Because AGEs enhance left ventricular hypertrophy (LVH) via the activation of nuclear factor-kappa B, it is considered that increased AGEs contribute to LVH in HT patients. The aim of this study was to investigate the effect of increased AGEs on LVH in them. Methods: Eighty five HT patients aged 65 ± 9 years were prospectively followed up for a year, whose blood pressure was controlled under 140/90mmHg. We assessed patients’ glucose and lipid metabolism and neurohumoral factors including plasma noradrenaline and renin activity as clinical characteristics. We measured serum malondialdehyde-modified LDL-cholesterol (MDA-LDL) and plasma pentosidine as parameters of oxidative stress and AGEs, respectively. Homeostasis model assessment ratio (HOMA-R), estimate glomerular filtration rate (eGFR) and left ventricular mass index (LVMI) were assessed as parameters of insulin resistance, renal function and LVH, respectively. All parameters were assessed before and after one-year observation period. We examined the change in each parameter from baseline to the value measured after the observation period ([[Unable to Display Character: &amp;#8895;]]MDA-LDL, [[Unable to Display Character: &amp;#8895;]]pentosidine, [[Unable to Display Character: &amp;#8895;]]HOMA-R and [[Unable to Display Character: &amp;#8895;]]LVMI). We divided patients into two groups based on the median of baseline pentosidine: high AGEs and low AGEs groups. We compared baseline values between the two groups. We analyzed the relationships among [[Unable to Display Character: &amp;#8895;]]MDA-LDL, [[Unable to Display Character: &amp;#8895;]]HOMA-R, [[Unable to Display Character: &amp;#8895;]]Pentosidine and [[Unable to Display Character: &amp;#8895;]]LVMI, and performed stepwise multiple regression analysis using parameters of clinical characteristics and AGEs to detect the predictors for the LVH progress after one year. Results: Baseline LVMI was significantly higher in the high AGEs group than in the low AGEs group (P&lt;0.05). [[Unable to Display Character: &amp;#8895;]]Pentosidine was positively correlated with [[Unable to Display Character: &amp;#8895;]]MDA-LDL (r=0.34, P&lt;0.01),[[Unable to Display Character: &amp;#8895;]]HOMA-R (r=0.37, P&lt;0.01) and [[Unable to Display Character: &amp;#8895;]]LVMI (r=0.39, P&lt;0.05). Multiple regression analysis detected pentosidine as a significant independent predictor for the LVH progress (β=0.407, P=0.005) (R2=0.315). Conclusion: Increased AGEs accelerated the LVH progress under condition of elevated oxidative stress or insulin resistance in HT patients.